Download PDF
Allgemeinmedizin up2date 2023; 04(04): 319-334
DOI: 10.1055/a-2114-8209
Spezifische Patientengruppen

Antipsychotika: Was der Allgemeinmediziner wissen sollte

Johanna Seifert
,
Hannah B. Maier
,
Sermin Toto
,
Dominik Dabbert
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Antipsychotika (AP) wurden ursprünglich entwickelt, um Symptome der Schizophrenie zu behandeln – heute werden sie auch häufig bei geriatrischen Patienten, v.a. an Demenz Erkrankten eingesetzt. Dieser Beitrag erläutert den Einsatz von AP bei Schizophrenie und Verhaltensauffälligkeiten bei Demenz gemäß den jeweiligen Behandlungsleitlinien. Auch die unerwünschten Wirkungen häufig verwendeter AP und ihre Behandlungsmöglichkeiten werden vorgestellt.

Schlüsselwörter

Antipsychotika - Demenz - Schizophrenie - Leitlinie - unerwünschte Arzneimittelwirkung


Publication History

Article published online:
21 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Next part of this series:

Episode 8: „Antipsychotika: Was der Allgemeinmediziner wissen sollte“Allgemeinmedizin up2date 2023; 04(04): p8-p8
DOI: 10.1055/a-2287-3706

 

  • Literatur

  • 1 Braslow JT, Marder SR. History of Psychopharmacology. Annu Rev Clin Psychol 2019; 15: 25-50
    CrossrefPubMedSearch in Google Scholar
  • 2 Leucht S, Corves C, Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
    CrossrefPubMedSearch in Google Scholar
  • 3 Krause M, Zhu Y, Huhn M. et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018; 268: 625-639
    CrossrefPubMedSearch in Google Scholar
  • 4 Lohse MJ, Seifert J, Bleich S. Psychopharmaka. In: Arzneiverordnungs-Report 2021. Springer; 2021: 689-725
    Search in Google Scholar
  • 5 Hessmann P, Dodel R, Baum E. et al. Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany. Int J Psychiatry Clin Pract 2018; 22: 232-239
    CrossrefPubMedSearch in Google Scholar
  • 6 Lenzer J. FDA warns about using antipsychotic drugs for dementia. BMJ 2005; 330: 922
    CrossrefPubMedSearch in Google Scholar
  • 7 Kiss N, Giezendanner S, Zeller A. Geriatric Psychiatry in Nursing Homes in the Canton Basel-Stadt - The View of General Practitioners. Praxis (Bern 1994) 2021; 110: 257-261
    CrossrefPubMedSearch in Google Scholar
  • 8 Siafis S, Tzachanis D, Samara M. et al. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol 2018; 16: 1210-1223
    CrossrefPubMedSearch in Google Scholar
  • 9 Kim SA. 5-HT1A and 5-HT2A Signaling, Desensitization, and Downregulation: Serotonergic Dysfunction and Abnormal Receptor Density in Schizophrenia and the Prodrome. Cureus 2021; 13: e15811
    CrossrefPubMedSearch in Google Scholar
  • 10 Seifert R. Basiswissen Pharmakologie. Heidelberg: Springer; 2021
    CrossrefSearch in Google Scholar
  • 11 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin: Springer; 2021
    CrossrefSearch in Google Scholar
  • 12 Bleich S, Dabbert D, Kropp S. et al. Handbuch Psychopharmaka – Deutsche Bearbeitung der englischsprachigen Version von Ric M. Procyshyn, Kalyna Z. Bezchlibnyk-Butler und J. Joel Jeffries. Göttingen: Hogrefe; 2022.
    CrossrefSearch in Google Scholar
  • 13 Gaebel W, Hasan A, Falkai P. S3-Leitlinie Schizophrenie. Heidelberg: Springer; 2019
    CrossrefSearch in Google Scholar
  • 14 Ostuzzi G, Vita G, Bertolini F. et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry 2022; 9: 614-624
    CrossrefPubMedSearch in Google Scholar
  • 15 Siskind D, Orr S, Sinha S. et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry 2022; 220: 115-120
    CrossrefPubMedSearch in Google Scholar
  • 16 Kishi T, Ikuta T, Matsui Y. et al. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychol Med 2019; 49: 772-779
    CrossrefPubMedSearch in Google Scholar
  • 17 Seibert M, Mühlbauer V, Holbrook J. et al. Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials. Alzheimers Res Ther 2021; 13: 131
    CrossrefPubMedSearch in Google Scholar
  • 18 Huang Y-Y, Teng T, Shen X-N. et al. Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis. Ageing Res Rev 2022; 75: 101568
    CrossrefPubMedSearch in Google Scholar
  • 19 Tampi RR, Tampi DJ, Balachandran S. et al. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis 2016; 7: 229-245
    CrossrefPubMedSearch in Google Scholar
  • 20 Watt JA, Goodarzi Z, Veroniki AA. et al. Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis. BMC Geriatr 2020; 20: 212
    CrossrefPubMedSearch in Google Scholar
  • 21 Yeh TC, Tzeng NS, Li JC. et al. Mortality Risk of Atypical Antipsychotics for Behavioral and Psychological Symptoms of Dementia: A Meta-Analysis, Meta-Regression, and Trial Sequential Analysis of Randomized Controlled Trials. J Clin Psychopharmacol 2019; 39: 472-478
    CrossrefPubMedSearch in Google Scholar
  • 22 Seppala LJ, Wermelink A, de Vries M. et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. J Am Med Dir Assoc 2018; 19: 371.e311-371.e317
    CrossrefPubMedSearch in Google Scholar
  • 23 Deuschl G, Maier W. Deutsche Gesellschaft für Neurologie. S3-Leitlinie Demenzen. Leitlinien für Diagnostik und Therapie in der Neurologie 2016. AWMF-Register-Nr.: 038–013.
  • 24 Mann NK, Mathes T, Sönnichsen A. et al. Potentially Inadequate Medications in the Elderly: PRISCUS 2.0—First Update of the PRISCUS List. Dtsch Arztebl Int 2023; 120: 3-10
    CrossrefPubMedSearch in Google Scholar
  • 25 Van Leeuwen E, Petrovic M, van Driel ML. et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 2018; 3: CD007726
    CrossrefPubMedSearch in Google Scholar
  • 26 Dabbert D, Toto S, Seifert J. Clozapin aus Sicht des Projekts „Arzneimittelsicherheit in der Psychiatrie". InFo Neurologie + Psychiatrie 2022; 24: 40-51
    CrossrefSearch in Google Scholar